Benitec Biopharma Limited (NASDAQ:BNTC) Given Consensus Rating of “Buy” by Analysts

Benitec Biopharma Limited (NASDAQ:BNTC) has earned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $26.00.

A number of research firms have commented on BNTC. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of Benitec Biopharma in a research report on Monday, May 19th. TD Cowen began coverage on shares of Benitec Biopharma in a research report on Monday, July 7th. They issued a “buy” rating on the stock.

Hedge Funds Weigh In On Benitec Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of BNTC. Police & Firemen s Retirement System of New Jersey purchased a new position in Benitec Biopharma during the 2nd quarter valued at about $38,000. Bank of America Corp DE boosted its holdings in Benitec Biopharma by 2,255.8% during the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 6,587 shares during the period. JPMorgan Chase & Co. purchased a new position in Benitec Biopharma during the 2nd quarter valued at about $80,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Benitec Biopharma during the 2nd quarter valued at about $93,000. Finally, New York State Common Retirement Fund purchased a new position in Benitec Biopharma during the 2nd quarter valued at about $95,000. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Trading Down 0.9%

NASDAQ BNTC opened at $13.85 on Friday. The firm’s 50-day moving average is $12.54 and its two-hundred day moving average is $13.38. Benitec Biopharma has a 12 month low of $8.06 and a 12 month high of $17.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.80 and a quick ratio of 14.80. The stock has a market capitalization of $363.56 million, a P/E ratio of -9.17 and a beta of 0.43.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.